Market Place
Sourcing Support
Gedeon Richter: Cariprazine Poised for Success
10 Apr 2024 //
PR NEWSWIRE
AbbVie gives Vraylar ad campaign `a lift` with new focus
09 May 2023 //
FIERCE PHARMA
Aurobindo`s Generic Cariprazine Receives Receives Approval in the U.S.
05 May 2023 //
FDA
AbbVie`s Vraylar approved to treat major depressive disorder
19 Dec 2022 //
FIERCEPHARMA
U.S. FDA Approves VRAYLAR as an Treatment for Major Depressive Disorder
16 Dec 2022 //
PRNEWSWIRE
The incidence of side effects decreased over time with cariprazine
18 Oct 2022 //
PRNEWSWIRE
Zydus`s Generic Cariprazine HCL Receives Approval in the U.S.
09 Sep 2022 //
FDA
AbbVie Submits sNDA to U.S. FDA for cariprazine in Major Depressive Disorder
22 Feb 2022 //
PRNEWSWIRE
Teva`s Generic Fluticasone & Salmeterol Receives Approval in the U.S.
13 Dec 2021 //
FDA
Zydus Cadila receives tentative approval from US FDA for Cariprazine Capsule
13 Dec 2021 //
EXPRESSPHARMA
Zydus Pharma`s Generic Cariprazine Receives Approval in the U.S.
07 Dec 2021 //
FDA
Gedeon Richter: Cariprazine is well tolerated in the early stage schizophrenia
13 Apr 2021 //
PRNESWIRE
Cariprazine Significantly Improved -ve Symptoms of Schizophrenia Based Data
08 Jul 2020 //
PRNEWSWIRE
Could AbbVie-Allergan lean on Vraylar scripts post-Humira?
19 Dec 2019 //
FIERCE PHARMA
Allergan elevator depicts bipolar symptoms in brand-new Vraylar ad campaign
10 Sep 2019 //
FIERCE PHARMA
Intra-Cellular drug fails bipolar depression study; shares fall 14%
08 Jul 2019 //
REUTERS
Allergan puts Vraylar on blockbuster track with new nod
29 May 2019 //
FIERCE PHARMA
Allergan`s Vraylar wins FDA approval for bipolar depression
28 May 2019 //
REUTERS
FDA accepts Allergan’s Vraylar for review
27 Sep 2018 //
PHARMA TIMES
Allergan Announces FDA Accepts Suppl. NDA For VRAYLAR® (cariprazine)
26 Sep 2018 //
PR NEWSWIRE
Allergan focuses on biopolar mania in first DTC push for Vraylar
10 Apr 2018 //
FIERCE PHARMA
Allergan notches third trial success for depression drug
04 Apr 2018 //
BIOPHARMA DIVE
Allergan, Richter prep for FDA OK with +ve PhIII for cariprazine in bipolar
04 Apr 2018 //
ENDPTS
Allergan to file cariprazine for major depressive episodes
19 Dec 2017 //
PHARMA TIMES
Allergan, Richter`s bipolar depression drug succeeds in key trial
19 Dec 2017 //
REUTERS
Allergan caps a bad day with news the FDA has kicked back a cariprazine
25 Sep 2017 //
ENDPTS
Allergan caps a bad day -FDA has kicked back a supplemental application for cariprazine
23 Sep 2017 //
ENDPTS
Allergan Receives Refusal to File Letter from FDA for Vraylar® cariprazine
22 Sep 2017 //
PR NEWSWIRE
Gedeon Richter`s Reagila (cariprazine) Receives Approval In Europe
19 Sep 2017 //
EMA
EU nod for Gedeon’s novel antipsychotic Reagila
19 Jul 2017 //
PHARMA TIMES
EMA’s CHMP Recommends Approval for Five New Medicines, Four New Biosimilars
19 May 2017 //
RAPS
FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine)
08 Mar 2017 //
PR NEWSWIRE
Allergan CEO: 2017 should be Kybella`s breakout year
12 Jan 2017 //
FIERCE PHARMA
Allergan and Richter push ahead despite PhIII fail for depression drug
08 Aug 2016 //
FIERCE BIOTECH
Allergan Announces US Availability of VRAYLAR™ for Bipolar Mania
17 Mar 2016 //
PR NEWSWIRE
Allergan, Gedeon Richter Plc. to Present Data on VRAYLAR at ACNP Annual Meeting
04 Dec 2015 //
PR NEWS WIRE
